Professional Documents
Culture Documents
Ace Inhibitors benazepril - Lotensin by Novartis captopril - Capoten by Bristol-Myers Squibb enalapril - Vasotec by Merck fosinopril - Monopril by Bristol-Myers Squibb imidapril - Not approved for human use in the USA - approved in Japan lisinopril - Prinivil by Merck or Zestril by Astra-Zeneca moexipril - Univasc by Schwarz Pharma quinapril - Accupril by Pfizer perindopril erbumine - Aceon by Rhone-Polenc Rorer ramipril - Altace by Hoechst Marion Roussel, King Pharmaceuticals trandolapril - Mavik by Knoll Pharmaceutical (BASF) ARBS - Angiotension II Receptor Blockers candesartan cilexetil - Atacand by Astra Merck eprosartan - Teveten irbesartan - Avapro by Sanofi losartan - Cozaar by Merck olmesartan medoxomil - Benicar by Sankyo Pharma telmisartan - Micardis valsartan - Diovan by Novartis
In Conclusion,...
High doses are better than low doses but doctors don't usually prescribe them - due to simple ignorance. Double-check your doc on this to be sure you are getting a high enough dose! Even if you improve to normal heart function and consider yourself "cured," a good CHF specialist will keep you on an ACE inhibitor for life, and that's smart. It may stop you from getting CHF again down the road - which can happen. ACE inhibitor use may reduce your zinc level so you might want to take a zinc supplement. Your sense of taste could possibly go goofy on you after starting an starting ACE inhibitor too - especially on captopril.
This Page
More CHFers Need To Take - And Keep Taking - ACE Inhibitors ACE Inhibitors Should Be Standard Treatment For CHF Aspirin, ACE Inhibitors, and Mortality ACE Inhibitors Slow Heart Damage Caused By CHF High Dose Better For CHF High Doses Better Once Again Higher Doses Well Tolerated In CHF Patients Losartan Eases ACE Inhibitor Cough ELITE 2 - Losartan Versus Captopril In Elderly Losartan Improves Heart Size Blood Levels Of Angiotensin II Point To Prognosis HOPE Trial Results HOPE Trial - Diabetic Results ARBs Slow Worsening Of Diabetic Nephropathy ACE Inhibitors & ARBs Reduce Death And Complications In CHFers ACE Inhibitors For CHFers With Low Blood Pressure Works Fine ACE Inhibitors Improve Artery "Stretchability" in CHF Patients Stomach Pain Side Effect Must Be Considered In ACE Inhibitor Patients NSAIDs (Indomethacin) & ACE Inhibitors Don't Mix NSAIDs Interfere With ACE Inhibitors Valsartan Better than Coreg Regarding Sexual Ability In Men ACE Inhibitors Help Patients With Extra Problems Even More ACE Inhibitors Help Prevent CHF In High-Risk Patients The CHARM trials for ARBs In Heart Failure ARB Plus ACE Inhibitor FDA-Approved For Heart Failure NEW
days. Title: Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. Authors: Javed Butler, Patrick Arbogast, James Daugherty, Manoj Jain, Wayne Ray, Marie Griffin. Source: June 2, 2004, Volume 43, Issue 11 Pages 2036-2043.
ELITE 2 Results
December 20, 1999 - The original ELITE trial showed 46% reduction in all-cause death and 64% reduction in SCD with losartan compared to captopril. ELITE 2 was done to study this. ELITE 2's primary endpoint was all-cause mortality. Secondary endpoints were SCD, all-cause hospitalizations, hospitalization for CHF, heart-related death, and heart attack - either fatal or nonfatal. There were 3,152 patients in the trial and 1,574 took 50mg captopril 3 times a day while 1,578 took 50mg losartan per day. In both groups, patients were mostly men with an average age of 72 years. Average EF was 31% in both groups. Eighty percent had ischemic CHF. About 25% in each group were taking a beta-blocker and 50% were on digoxin (Lanoxin). No difference was seen in SCD, heart failure deaths, heart attack, or stroke between the groups. The event rate was 16% in the captopril group and 18% in the losartan group. ELITE II did not confirm ELITE's finding that losartan is better than captopril for improving survival. No differences were seen in all-cause mortality, sudden cardiac death, resuscitated cardiac arrest, or hospitalizations. Title: ELITE II - Evaluation of Losartan in The Elderly Study, The Losartan Heart Failure Survival Study Presented by: Philip A. Poole-Wilson, MD and Betram Pitt, MD.
losartan per day for 8 months. At follow-up, "intra-arterial pressure was reduced from 165/102mm Hg to 145/91mm Hg at rest; and from 193/104mm Hg to 179/96mm Hg during exercise." Total peripheral resistance was reduced 12 to 15%. Cardiac index and heart rate remained unchanged. During exercise, heart output increased 7% to 9% but was unchanged at rest. Blood pressure measured over 24 hours with patients moving around freely went down 10% to 13%. There was a 27% reduction in left ventricular size in 18 patients with enlarged hearts. Source: Am Heart J 2000;140:624-630
Source: Reuters Health and The 16th annual meeting of the American Society of Hypertension
While both heart drugs lowered diastolic blood pressure, indomethacin "significantly reduced their effectiveness." High blood pressure patients taking these drugs along with indomethacin need to be monitored for proper blood pressure control. Source: Hypertension 2000;36:461-465.
dose of 32mg a day, as patients tolerated it. Patients were seen at 2, 4, and 6 weeks; at 6 months and then every 4 months. Primary end point for each sub-trial was heart-related death or CHF hospitalization. Primary outcome for the overall program (CHARM-Overall) was all-cause death. CHARM included 7,601 CHFers. Patients with kidney failure, high potassium, high blood pressure, heart attack, stroke, or open-heart surgery in the previous 4 weeks were not included in the trial. Patients were being treated with standard therapy including beta-blockers, diuretics, digoxin (Lanoxin), Aldactone (spironolactone), and sometimes ACE inhibitors, at close to target doses.
CHARM-ALTERNATIVE
CHARM-Alternative included 2,028 CHFers who did not tolerate ACE inhibitors. They got standard therapy, or standard therapy plus candesartan. The most common reasons for ACE inhibitor intolerance was cough (72%), low blood pressure (13%), and kidney dysfunction (12%). Candesartan reduced relative risk of heart-related death or CHF hospitalization 23%. This is similar to the risk reduction seen in the SOLVD ACE inhibitor trial. With an average follow-up of 34 months, 33% of candesartan patients had reached the end point versus 40% of placebo patients. That means you need to treat 14 patients with candesartan to prevent one patient from having heart-related death or CHF hospitalization. Candesartan was well tolerated by these ACE inhibitor-intolerant patients: 22% dropped out versus 19% of placebo patients. Four percent of candesartan patients stopped taking the drug due to low blood pressure versus 1% of placebo patients, decreased kidney function (6% versus 3%), and high potassium levels (2% versus 0.3%). Angioedema was rare in CHARM-Alternative, with only one of 39 patients with a history of it having an episode that made them quit taking candesartan. So angioedema on an ACE inhibitor should not prevent a CHFer from trying an ARB.
CHARM-ADDED
CHARM-Added included 2,548 CHFers taking an ACE inhibitor. Ninety-six percent were at target dose. Fifty-five percent were also taking a beta-blocker and 17% took spironolactone. Candesartan reduced relative risk of heart-related death or CHF hospital admission 15%. With an average 41 months followup, primary end point was reached in 42% of placebo patients and 38% of candesartan patients. There were relatively few side effects when the ARB was added to ACE inhibitor therapy. However, blood potassium level and kidney function need to be monitored. Eight percent of candesartan patients stopped due to worsening kidney function versus 4% of placebo patients. Three percent withdrew due to low potassium levels versus less than 1% of placebo patients.
CHARM-PRESERVED
CHARM-Preserved included 3,023 CHFers. The lead researcher for this sub-trial said that although almost half of all CHFers seen in the "real world" have normal LV systolic function, there are few trials done with just these patients - diastolic heart failure. After an average 37 months follow-up, there was no difference in risk of heart-related death, but fewer candesartan patients were hospitalized for CHF (402) than placebo patients (566). A 40% relative risk reduction was seen in development of new diabetes in candesartan patients. This is similar to the HOPE and LIFE trials and suggests that blocking the renin-angiotensin system with ACE inhibitors or ARBs helps prevent diabetes.
CHARM-OVERALL
Summarizing CHARM-Overall, Dr. Marc Pfeffer said that after an average follow-up of 38 months, analyzing the 3 studies showed a 9% relative reduction in all-cause death. In absolute terms, that is 23% of patients dying versus 25% in the placebo group. With candesartan, relative risk of heart-related death was reduced 12%, hospital admission for CHF 21%, and combined heartrelated death or hospital admission for CHF 16%. These results were similar in men and women, and in CHFers of all ages. Benefit was seen when added to current therapy of ACE inhibitors and beta-blockers. This means that 23 patients need to take candesartan for 3 years in order to prevent one heart-related death or CHF hospitalization. CHARM-Overall showed that candesartan did not greatly reduce risk of heart attack, stroke, or need for procedures like bypass or angioplasty, but new-onset diabetes was reduced (163 cases or 6%) versus placebo (202 or 7%). In CHARM-Overall, candesartan did cause low blood pressure in 4% of CHFers versus 2% of placebo patients, reduced kidney function in 6% versus 3% of placebo patients, and high potassium level in 2% versus less than 1%. This shows that ARB patients need routine blood testing.
May 19, 2005 - Adding the ARB Atacand (candesartan cilexetil) to ACE inhibitor therapy was FDA approved May 18, 2005 for treating class 2 to class 4 CHFers. The official recommendation is for CHFers with an EF of 40% or less. This came from CHARM-Added trial results. The ARB was already FDA-approved for CHFers who can't tolerate ACE inhibitors, based on another part of the CHARM trial called CHARM-Alternative. When used with an ACE inhibitor for heart failure, Atacand's dose is FDA-recommended to start at 4 mg once a day and rise to a target dose of 32 mg once a day. Source: www.fda.gov/cder/foi/label/2005/020838s022lbl.pdf Source: www.fda.gov/cder/foi/appletter/2005/020838s022ltr.pdf Source: Heartwire.
All information on this site is opinion only. All concepts, explanations, trials, and studies have been re-written in plain English and may contain errors. I am not a doctor. Use the reference information at the end of each article to search MedLine for more complete and accurate information. All original copyrights apply. No information on this page should be used by any person to affect their medical, legal, educational, social, or psychological treatment in any way. I am not a doctor. This web site and all its pages, graphics, and content copyright 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005 Jon C.
Talk to Jon
Site Index